Liver tumors represent the third largest group of pediatric intra-abdominal tumors, after neuroblastoma and kidney tumors. They represent approximately 1% of all pediatric tumors and include hepatoblastoma (HB), hepatocellular carcinoma (HCC), unspecified hepatocellular neoplasm (HCN NOS), and undifferentiated embryonic sarcoma (UESL).

The development of a national registry for pediatric patients with liver tumors will provide an overview of clinical and epidemiological data, as well as therapeutic strategies, and short- and long-term outcomes. We will prospectively collect clinical, biological, radiological, radiological, histological, histological, genetic and molecular pathology data from patients under 18 with liver tumors, diagnosed in Switzerland, and from the Geneva biobank BaHop. All patients or their legal representatives must have signed the consent form. The 9 institutions of the Swiss Pediatric Oncology Group (SPOG); namely Aarau, Berne, Basel, Bellinzona, Geneva, Lausanne, Lucerne, St Gal & Zurich; will participate in the data collection. We will establish a national tumor board to discuss all cases of liver tumors and put in place national recommendations for the management of these patients, based on international recommendations following the results of the PHITT study.

The protocol will be submitted for approval by the Swiss Ethics Committee (EC) and will be presented to SPOG.

What does this study bring to patients?

The SWISSLIVERRE project makes it possible to standardize therapeutic strategies for liver tumors in Switzerland, by establishing a national tumor board. The collection of biological and tissue samples in the BaHop can contribute to the evaluation of prognostic biomarkers and biomarkers associated with toxicity in this population in order to improve the prognosis and quality of life of these patients.